trial

Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics

NCTId NCT03730857
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 111 (actual)
Sponsored by Calo Psychiatric Center
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
111 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
None
Start
2008-01
Primary completion
2008-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineRisperidonePaliperidone

Sponsors

Calo Psychiatric CenterLead Sponsor

Investigators

1
For-Wey Lung, MD, ScDPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
111
Phase
PHASE1
Primary Completion Date
2008-12
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Risperidone
drug
Paliperidone
drug
lead_sponsor
Calo Psychiatric Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
For-Wey Lung, MD, ScD
person